Cargando…
The influence of SARS‐CoV‐2 infection on expression of drug‐metabolizing enzymes and transporters in a hACE2 murine model
Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection and the resulting Coronavirus disease 2019 emerged in late 2019 and is responsible for significant morbidity and mortality worldwide. A hallmark of severe COVID‐19 is exaggerated systemic inflammation, regarded as a “cytokine sto...
Autores principales: | Deshpande, Kiran, Lange, Keith R., Stone, William B., Yohn, Christine, Schlesinger, Naomi, Kagan, Leonid, Auguste, Albert J., Firestein, Bonnie L., Brunetti, Luigi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10155506/ https://www.ncbi.nlm.nih.gov/pubmed/37133236 http://dx.doi.org/10.1002/prp2.1071 |
Ejemplares similares
-
Colchicine in COVID-19: an Old Drug, New Use
por: Schlesinger, Naomi, et al.
Publicado: (2020) -
Fatal Neurodissemination and SARS-CoV-2 Tropism in K18-hACE2 Mice Is Only Partially Dependent on hACE2 Expression
por: Carossino, Mariano, et al.
Publicado: (2022) -
Genetic variability of human angiotensin‐converting enzyme 2 (hACE2) among various ethnic populations
por: Li, Quan, et al.
Publicado: (2020) -
Comparative pathology of the nasal epithelium in K18-hACE2 Tg mice, hACE2 Tg mice, and hamsters infected with SARS-CoV-2
por: Yu, Pin, et al.
Publicado: (2022) -
Exploring the disruption of SARS-CoV-2 RBD binding to hACE2
por: Carter, Camryn, et al.
Publicado: (2023)